CompletedNCT06058039
NMRA-335140 safety and effects in depression
About this title
Read the official source — NCT06058039Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 70 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: December 21, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 422
- Sponsor
- Neumora Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06058039
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos, United States · Irvine, United States · Long Beach, United States
56 more locations
- San Diego, United States
- San Francisco, United States
- New Haven, United States
- Brandon, United States
- Hialeah, United States
- Jacksonville, United States
- Miami, United States
- Miami Beach, United States
- Miami Springs, United States
- Palm Bay, United States
- Pembroke Pines, United States
- Pompano Beach, United States
- Saint Augustine, United States
- Atlanta, United States
- Decatur, United States
- Savannah, United States
- Springfield, United States
- St Louis, United States
- Omaha, United States
- Berlin, United States
- New York, United States
- Staten Island, United States
- Charlotte, United States
- Austin, United States
- DeSoto, United States
- Fort Worth, United States
- Plano, United States
- Cherven Bryag, Bulgaria
- Sofia, Bulgaria
- Kardzhali, Bulgaria
- Pleven, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Pilsen, Czechia
- Prague, Czechia
- Kladno, Czechia
- Helsinki, Finland
- Turku, Finland
- Oulu, Finland
- Clermont-Ferrand, France
- Douai, France
- Montpellier, France
- Angers, France
- La Roche-sur-Yon, France
- Poitiers, France
- Berlin, Germany
- Hamburg, Germany
- Suchy Las, Poland
- Bydgoszcz, Poland
- Wroclaw, Poland
- Lublin, Poland
- Bialystok, Poland
- Gdansk, Poland
- Lund, Sweden
- Stockholm, Sweden
- Czechia
Questions about this study
What did researchers investigate?
Researchers compared NMRA-335140 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Neumora Therapeutics, Inc.
Did this study involve medication?
Yes. The study involved medication, including NMRA-335140 and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
